Middle East supply chain disruption
Geopolitical tensions have increased freight costs and transit times; if prolonged, could impact Asia business recovery and margins.
high · management_commentary
Ajanta Pharma Ltd — Q4 FY26
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US FDA observations at Paithan plant
Five observations received; while management expects no immediate impact, any escalation could affect filings or existing product supplies.
medium · analyst_questionPrice erosion in US generics and Africa institutional
Both markets are tender-driven and competitive; management factors erosion into guidance but unexpected acceleration could pressure margins.
medium · analyst_questionPromoter share pledging by non-executive brothers
Two promoter brothers have increased borrowing against shares for their own businesses, though no pledge on Ajanta shares; could raise governance concerns.
low · analyst_question